Nov 6, 2025 6:00 PM Eastern Standard Time MedX Announces Final Closing of Non-Brokered Private Placement Share MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. ("MedX†or the "Company†) (TSX-V: MDX) is pleased to announce that, further to its Press Release dated October 6, 2025, announcing an Initial Closing, it has completed final Closings of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated July 25, 2025. The Final Closings comprised the is ...

Core Insights - MedX Health Corp. has appointed Dr. Symon D. Cotton as Strategic Advisor on AI and Product Development, enhancing its leadership in teledermatology and non-invasive skin analysis [1][5][6] Company Overview - MedX Health Corp. is a leader in non-invasive skin assessment and teledermatology, utilizing its proprietary SIAscopy® technology integrated into the DermSecure® platform for accurate imaging of skin lesions [6] - The company’s products are cleared for use in 38 territories worldwide, including Canada, the U.S., Australia, and the European Union [6] Appointment of Dr. Symon Cotton - Dr. Cotton is recognized for his contributions to medical technology innovation and has a background in engineering, biology, and computation [2][4] - He played a key role in the development of SIAscopy®, the first technology for non-invasive measurement of melanin, hemoglobin, and collagen in the skin [3] - His expertise in AI-driven analytics and medical imaging aligns with MedX's strategic goals to enhance diagnostic accuracy and scalability [4] Strategic Goals - Dr. Cotton aims to leverage MedX's imaging database and DermSecure® platform to improve early skin cancer detection globally [5] - The CEO of MedX, John Gevisser, emphasized that Dr. Cotton's experience will help maintain the company's leadership in skin optics and machine learning [5]